Repro Med Systems Inc (REPR)

[blue_skies]

Q2 2019 Highlights

Net sales rose 18.8% to $5.3 million. Second quarter in a row of record earnings. Expect earnings growth to accelerate as Grifols Xembify sales beginning to kick in during 2020. Management believes Xembify sales to be additive and will not cannibalize existing sales.

Gross margin improved to 65.0% Expect gross margins to continue improving with future sales growth and production efficiencies. Production efficiencies are like an annuity that keep paying benefits quarter after quarter.

The company has no debt and $3.8 million of cash and cash equivalents.

The above are a few of the reason I see this as a safe growth stock scenario.

Do your own DD.